EUCTR2006-002982-38-DE进行中（未招募）不适用
A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - Rebif FLEXible dosing in early Multiple Sclerosis (REFLEX)
Merck Serono S.A. - Geneva, an affiliate of Merck KGaA Darmstadt, Germany0 个研究点目标入组 480 人开始时间: 2006年10月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •· Subject with a single, first clinical event suggestive of MS within the last 60 days prior to SD1, which is the day of randomisation (clock starts 24 hours after onset). The event must be a new neurological abnormality present for at least 24 hours, either mono- or polysymptomatic, other than a paresthesia, vegetative or cerebral dysfunction;
- •· Subject has at least two clinically silent lesions on the T2-weighted MRI scan, with a size of at least 3 mm, at least one of which is ovoid or periventricular or infratentorial;
- •· EDSS 0 - 5.0 at at least one time point during the screening period before start of treatment;
- •· Subject is between 18 and 50 years old, inclusive;
- •· Subject is willing to follow study procedures;
- •· Subject has given written informed consent;
- •· If female, subject must:
- •a) be neither pregnant nor breast-feeding nor attempting to conceive
- •b) use a highly effective method of contraception. A highly effective method of contraception is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner.*
- •*Note for subjects using a hormonal contraceptive method: No formal drug interaction studies have been carried out with IFN-beta-1a or HSA free IFN beta 1a. As interferons have been reported to exert an inhibitory activity on hepatic microsomal enzymes, it is unlikely that the clearance of oral contraceptives would be increased and result in decreased efficacy. In over 10,000 patient-years of clinical trial experience with Rebif®, there has never been any indication of an interaction with oral contraceptives.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •· Subject has a diagnosis of Multiple Sclerosis (per McDonald criteria 2005);
- •· Subject has any other disease that could better explain the patient’s signs and symptoms;
- •· Subject has complete transverse myelitis or bilateral optic neuritis;
- •· Subject uses or has used any other approved MS DMD;
- •· Subject has used any investigational drug or undergone an experimental procedure within 12 weeks prior to SD1;
- •· Subject received oral or systemic corticosteroids or ACTH within 30 days prior to SD1;
- •· Subject has total bilirubin > 2.5x upper limit of normal,
- •· Subject has total aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase > 2.5 times the upper limit of normal values;
- •· Subject has inadequate bone marrow reserve, defined as a total white blood cell count < 3.0 x 109/L, platelet count < 75 x 109/L, haemoglobin < 100 g/L.
- •· Subject suffers from current autoimmune disease;
- •· Subject suffers from major medical or psychiatric illness (including history of severe depressive disorders and/or suicidal ideation) that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol;
- •· Subject has a history of seizures not adequately controlled by treatment;
- •· Subject has cardiac disease, such as angina, congestive heart failure or arrhythmia;
- •· Subject has a known allergy to IFN-beta or the excipient(s) of the study medication;
- •· Subject has any condition that could interfere with the MRI evaluation;
- •· Subject has a known allergy to gadolinium-DTPA;
- •· Subject has previously participated in this study;
- •· Subject has participated in any clinical trial within the past 6 months prior to SD1;
- •· Subject has received any immunomodulatory or immunosuppressive therapy at any time prior to SD1, including, but not limited to, the following products: any interferon, glatiramer acetate (Copolymer I), cyclophosphamide, cyclosporine, methotrexate, linomide, azathioprine, mitoxantrone, teriflunomide, laquinimod, cladribine, total lymphoid irradiation, anti-lymphocyte monoclonal antibody treatment (e.g. natalizumab, alemtuzumab/Campath, anti-CD4), IvIg, cytokines or anti-cytokine therapy;·Subject has received any experimental MS treatment prior to SD1, including, but not limited to, any statins (if given to prevent MS) and pentoxyfilline;
- •· Subject has a history of alcohol or drug abuse;
- •· Subject has intolerance or any contraindication to both paracetamol (acetaminophen) and ibuprofen;
- •· Inability to administer subcutanteous injections either by self or by caregiver;
- •· Subject has moderate to severe renal impairment.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy in patients with breast cancer that spread to other tissues.HER2-negative metastatic breast cancer.MedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2011-005335-97-DEF. Hoffmann-La Roche Ltd480
进行中（未招募）
1 期
24 week efficacy and 3-year safety and efficacy of secukinumab in active Psoriatic ArthritisMedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000004859Psoriatic ArthritisEUCTR2013-004002-25-BGovartis Pharma Services AG414
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy in patients with breast cancer that spread to other tissues.HER2-negative metastatic breast cancer.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2011-005335-97-BEF. Hoffmann-La Roche Ltd480
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Atezolizumab or Placebo in Combination with Neoadjuvant Doxorubicin + Cyclophosphamide Followed by Paclitaxel + Trastuzumab +Pertuzumab in Early HER2-Positive Breast CancerEarly Human epidermal growth factor receptor 2 (HER2)-positive breast cancerEUCTR2018-001881-40-PLF. Hoffmann-La Roche Ltd454
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Atezolizumab or Placebo in Combination with Neoadjuvant Doxorubicin + Cyclophosphamide Followed by Paclitaxel + Trastuzumab + Pertuzumab in Early HER2-Positive Breast CancerEarly Human epidermal growth factor receptor 2 (HER2)-positive breast cancerMedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001881-40-ITF. HOFFMANN - LA ROCHE LTD.283